iNKT Cell-Based Immunotherapy for Sepsis ID: 2020-044
An innovative therapeutic strategy targeting both hyperinflammatory and immunosuppressive phases of sepsis.
Photo by starlineart - stock.adobe.com
Technology Overview
This novel therapeutic approach employs a 'double-hit' treatment using invariant natural killer T (iNKT) cells to combat sepsis. It involves the sequential administration of OCH and α-galactosylceramide (α-GalCer) to overcome iNKT cell anergy and stimulate a robust immune response, aiming to reduce sepsis-related morbidity and mortality.
Key Advantages
- Targets both hyperinflammatory and immunosuppressive phases of sepsis
- Restores host immunocompetence, minimizing secondary infection risks
- Leverages glycolipid agonists that work across species barriers, enhancing its applicability to diverse human populations
- Induces IFN-γ burst and stimulates immune responses, including NK cell activation and increased MHC II expression on macrophages
Problems Addressed
- Overcomes i
- NKT cell anergy, which hampers repeated therapeutic interventions
- Addresses both immediate and prolonged phases of immune dysfunction in sepsis
- Minimizes risks of secondary infections by restoring host immunocompetence
Market Applications
- Therapeutic interventions for sepsis and complex inflammatory conditions
- Development of novel immunotherapies targeting immune system modulation
- Potential application in treating other diseases characterized by immune dysfunction
Additional Information
Technology ID: 2020-044
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report